CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR

Oncotarget

Volumn 5, Issue 7, 2014, Pages 1969-1986

  Wang, Tianxiao ^a   Yang, Jingxuan ^b   Xu, Jianwei ^a   Li, Jian ^a   Cao, Zhe ^a   Zhou, Li ^a   You, Lei ^a   Shu, Hong ^a   Lu, Zhaohui ^a   Li, Huihua ^c   Li, Min ^b   Zhang, Taiping ^a   Zhao, Yupei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CHIP; EGFR; Pancreatic cancer; Ubiquitination

Indexed keywords

CARBOXYL TERMINUS OF HEAT SHOCK PROTEIN 70 INTERACTING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; KI 67 ANTIGEN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; STUB1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR DIFFERENTIATION; UBIQUITINATION; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; CHEMISTRY; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PANCREATIC NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL LINE;

AGED; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ERLOTINIB HYDROCHLORIDE; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KI-67 ANTIGEN; MALE; MICE; MICE, NUDE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84898961547     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1890     Document Type: Article

References (33)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M. Pancreatic cancer. Lancet. 2011; 378(9791):607-620.
3. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ and Arnoletti JP. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res. 2007; 143(1):20-26.
4. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ and Arnoletti JP. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007; 141(4):464- 469.
5. Yarden Y and Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127- 137.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-1966.
7. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ and Arnoletti JP. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol. 2007; 14(7):2150-2158.
8. Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Marten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut. 2013; 62(5):751-759.
9. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-20937.
10. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V and Band H. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem. 2003; 278(16):13829-13837.
11. Jang KW, Lee JE, Kim SY, Kang MW, Na MH, Lee CS, Song KS and Lim SP. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation. J Thorac Oncol. 2011; 6(4):679-687.
12. Kajiro M, Hirota R, Nakajima Y, Kawanowa K, So-ma K, Ito I, Yamaguchi Y, Ohie SH, Kobayashi Y, Seino Y, Kawano M, Kawabe Y, Takei H, Hayashi S, Kurosumi M, Murayama A, et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol. 2009; 11(3):312-319.
13. Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X, He S, Qiang F, Li A, Shu Y, Roe OD, Li G and Zhou JW. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut. 2013; 62(4):496-508.
14. Su CH, Wang CY, Lan KH, Li CP, Chao Y, Lin HC, Lee SD and Lee WP. Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal. 2011; 23(11):1824-1830.
15. Ahmed SF, Deb S, Paul I, Chatterjee A, Mandal T, Chatterjee U and Ghosh MK. The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J Biol Chem. 2012; 287(19):15996-16006.
16. Esser C, Scheffner M and Hohfeld J. The chaperoneassociated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem. 2005; 280(29):27443-27448.
17. Pryczynicz A, Guzinska-Ustymowicz K, Kemona A and Czyzewska J. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008; 28(2B):1399-1404.
18. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S and Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999; 4(6):1029-1040.
19. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J and Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol. 2001; 3(1):93-96.
20. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS and Nyati MK. Wildtype EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia. 2012; 14(8):670-677.
21. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C and Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A. 2002; 99(20):12847-12852.
22. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W and Kasuga M. Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas. 2002; 24(1):42- 46.
23. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH and Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006; 168(3):962-972.
24. Watanabe M, Nobuta A, Tanaka J and Asaka M. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer. 1996; 67(2):264-268.
25. Goi T, Shipitsin M, Lu Z, Foster DA, Klinz SG and Feig LA. An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J. 2000; 19(4):623-630.
26. Leu TH and Maa MC. Functional implication of the interaction between EGF receptor and c-Src. Front Biosci. 2003; 8:s28-38.
27. Rojas M, Yao S and Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem. 1996; 271(44):27456-27461.
28. Xu T, Zhou Q, Zhou J, Huang Y, Yan Y, Li W, Wang C, Hu G, Lu Y and Chen J. Carboxyl terminus of Hsp70- interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci. 2011; 102(5):959-966.
29. Lu YY, Jing DD, Xu M, Wu K and Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol. 2008; 14(35):5403-5411.
30. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J and Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 2008; 14(16):5142-5149.
31. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-5909.
32. Wen J, Luo KJ, Hu Y, Yang H and Fu JH. Metastatic Lymph Node CHIP Expression is a Potential Prognostic Marker for Resected Esophageal Squamous Cell Carcinoma Patients. Ann Surg Oncol. 2013.
33. Liang ZL, Kim M, Huang SM, Lee HJ and Kim JM. Expression of carboxyl terminus of Hsp70-interacting protein (CHIP) indicates poor prognosis in human gallbladder carcinoma. Oncol Lett. 2013; 5(3):813-818.